FY2026 EPS Estimate for electroCore Boosted by Analyst

electroCore, Inc. (NASDAQ:ECOR) – Equities research analysts at HC Wainwright lifted their FY2026 earnings per share estimates for shares of electroCore in a note issued to investors on Thursday, November 5th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($1.06) per share for the year, up from their previous estimate of ($1.34). The consensus estimate for electroCore’s current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for electroCore’s Q4 2026 earnings at ($0.05) EPS, Q1 2027 earnings at ($0.05) EPS, Q2 2027 earnings at ($0.04) EPS, Q3 2027 earnings at ($0.04) EPS, Q4 2027 earnings at $0.05 EPS and FY2027 earnings at ($0.06) EPS.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of electroCore in a research note on Monday, September 21st. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $18.00.

electroCore Stock Down 1.0%

NASDAQ ECOR opened at $7.18 on Monday. electroCore has a 52 week low of $4.41 and a 52 week high of $12.70. The company has a 50 day moving average price of $9.23 and a 200 day moving average price of $7.76. The firm has a market cap of $64.76 million, a PE ratio of -5.17 and a beta of 1.23.

electroCore (NASDAQ:ECOR) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.14. The company had revenue of $9.69 million for the quarter, compared to analysts’ expectations of $10.93 million.

Insider Buying and Selling

In related news, Director Thomas J. Errico acquired 5,000 shares of the business’s stock in a transaction on Thursday, August 13th. The shares were bought at an average cost of $9.85 per share, with a total value of $49,250.00. Following the completion of the transaction, the director directly owned 343,332 shares of the company’s stock, valued at $3,381,820.20. This trade represents a 1.48% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Joshua Lev sold 12,000 shares of the business’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $10.22, for a total value of $122,640.00. Following the transaction, the chief financial officer owned 84,889 shares in the company, valued at approximately $867,565.58. This represents a 12.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 20,000 shares of company stock valued at $200,120. Corporate insiders own 7.80% of the company’s stock.

Hedge Funds Weigh In On electroCore

A hedge fund recently bought a new stake in electroCore stock. WealthShield Partners LLC purchased a new stake in electroCore, Inc. (NASDAQ:ECOR) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 25,978 shares of the company’s stock, valued at approximately $157,000. WealthShield Partners LLC owned approximately 0.32% of electroCore at the end of the most recent quarter. Hedge funds and other institutional investors own 26.74% of the company’s stock.

About electroCore

electroCore, Inc (NASDAQ: ECOR) is a commercial-stage medical device company focused on bioelectronic medicine and non-invasive vagus nerve stimulation (nVNS). Its technology is designed to stimulate the vagus nerve through the neck without requiring surgery or implanted components.

The company’s primary prescription product is gammaCore, a handheld nVNS device used for the acute treatment of pain associated with migraine and episodic cluster headaches in adults. electroCore also markets consumer-oriented products, including Truvaga, a handheld vagus nerve stimulation device positioned for general wellness applications.